Clinical Trial Update: Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention [Phase 1]

View source ↗

Summary

Phase 1 study from Stanford evaluating point-of-care pharmacogenomic testing to tailor isoniazid dosing for tuberculosis prevention; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• ISONIAZID (ISONIAZID)

Snippet

Sponsor: Stanford University | Conditions: Tuberculosis Infection, Isoniazid Adverse Reaction | Phase 1 | Status: COMPLETED